Hebei Lansheng Biotech Co., Ltd.
Beijing Multigrass Formulation Co., Ltd.

After three lost glyphosate-cancer trials, Bayer investors fear litigation ‘avalanche’ will further harm company’s reputationqrcode

Apr. 16, 2020

Favorites Print
Apr. 16, 2020
By Tim Loh and Eyk Henning

Two influential shareholder advisory groups are split on whether investors should support Bayer AG’s management at its upcoming annual meeting, a year after a damaging no-confidence vote.

Glass Lewis & Co. still sees risks brought about by Bayer’s takeover of agriculture giant Monsanto, advising shareholders to abstain rather than vote to endorse Chief Executive Officer Werner Baumann’s actions in 2019. While Institutional Shareholder Services Inc. recommended backing Baumann and his team, it expressed concern that litigation related to the Roundup weedkiller could further hurt the company’s value and reputation.

Concerns linger over Baumann’s strategic choices after he helped orchestrate the $63 billion deal that brought Bayer an avalanche of U.S. lawsuits from people claiming Roundup causes cancer. Three lost trials and at least 48,000 more suits have spurred investor flight, wiping tens of billions of dollars off Bayer’s valuation.

Bayer acknowledged in February that the losses from Roundup could force it to sell assets, issue new equity or borrow money at unfavorable terms. Bayer insists the herbicide is safe and has appealed the losing verdicts.

Source: Bloomberg

Picture 0/1200

More from AgroNews


2020 Biologicals Special 2020 Latin America Focus
2020 Formulation & Adjuvant Technology Annual Review 2019
Chinese issue of Annual Review 2019 2019 CRO & CRAO Manual
I wanna post a press Comment


Subscribe Email: *
Mobile Number:  


Picture 0/1200

Subscribe to daily email alerts of AgroNews.